➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Moodys
Baxter
Dow
McKinsey

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DARIFENACIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Darifenacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00127270 ↗ Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Procter and Gamble Phase 4 2005-05-01 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00127270 ↗ Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Novartis Phase 4 2005-05-01 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00170755 ↗ A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder Completed Novartis Phase 3 2002-04-01 This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
NCT00170768 ↗ Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over Completed Novartis Phase 2 2005-02-01 The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Darifenacin

Condition Name

Condition Name for Darifenacin
Intervention Trials
Overactive Bladder 5
Healthy 3
Overactive Bladder Syndrome 2
Bioequivalency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Darifenacin
Intervention Trials
Urinary Bladder, Overactive 10
Pain, Postoperative 1
Nocturia 1
Enuresis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Darifenacin

Trials by Country

Trials by Country for Darifenacin
Location Trials
United States 87
Germany 8
Canada 2
Uruguay 2
Colombia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Darifenacin
Location Trials
New Jersey 6
Missouri 5
California 5
Kansas 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Darifenacin

Clinical Trial Phase

Clinical Trial Phase for Darifenacin
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Darifenacin
Clinical Trial Phase Trials
Completed 13
Terminated 2
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Darifenacin

Sponsor Name

Sponsor Name for Darifenacin
Sponsor Trials
Novartis 9
Procter and Gamble 6
Bayer 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Darifenacin
Sponsor Trials
Industry 22
Other 7
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Colorcon
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.